BIOCON BIOLOGICS LIMITED UNIT II

Factory (Manufacturer)

Company Introduction:

BIOCON BIOLOGICS LIMITED UNIT II is a manufacturing facility located in India, functioning as an integral part of Biocon Biologics Ltd. Biocon Biologics is a prominent global biopharmaceutical company focused on developing and manufacturing affordable biosimilars and novel biologics.

This unit operates as a factory, primarily engaged in the large-scale production of a wide range of biopharmaceutical products. Its core activities involve advanced manufacturing processes for recombinant proteins, monoclonal antibodies, and other complex biological molecules. These products are critical for treating various therapeutic areas such as diabetes, oncology, and autoimmune diseases.

The facility operates under stringent international quality standards and complies with global regulatory requirements, including those mandated by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This ensures the safety, efficacy, and high quality of its manufactured products. BIOCON BIOLOGICS LIMITED UNIT II plays a crucial role in Biocon Biologics' global supply chain, contributing significantly to the company's mission of providing high-quality, cost-effective biosimilars and biologics to patients across the world. Its operations encompass fermentation, purification, formulation, and fill-finish processes, all supported by robust quality control and assurance systems.

BIOCON BIOLOGICS LIMITED UNIT II manufactures or sells a range of biosimilar products. These include Insulin Glargine, Recombinant Human Insulin, Insulin Aspart, Trastuzumab, Bevacizumab, Pegfilgrastim, Adalimumab, and Etanercept. These products primarily serve therapeutic areas such as diabetes, oncology, and immunology.